Fulcrum Therapeutics Starts Phase 3 Trial of Muscle Disorder Drug for COVID-19

Fulcrum Therapeutics has begun a phase 3 clinical trial in the U.S. of its investigational anti-inflammatory drug losmapimod for the treatment of hospitalized COVID-19 patients.

The trial will enroll 400 hospitalized patients at risk of progression to critical illness based on age and elevated systemic inflammation. Preliminary results from the trial are expected in the fourth quarter.

Fulcrum licensed the drug from GlaxoSmithKline in April 2019. GSK ended its development of the product after disappointing results from a phase 3 study in 2015. — Jordan Williams